Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why ↗
Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.
2 sources
- The Economic Times Markets · 6 Oct, 14:00 IST
- The Economic Times Stocks · 6 Oct, 14:00 IST
Open on desktop to take part.
0 comments
Comments are posted by users and are not reviewed by Bazaar Updates.
Open on desktop to take part.
Sign in to comment.
No comments yet.